OR WAIT null SECS
The Evolving Biologic Landscape for PsA Care, with Philip Mease, MD
Mease discussed the expanding treatment landscape for PsA and how the field is integrating new biologics.
Biologics have grown to be a valuable option in the toolset for treating psoriatic arthritis (PsA), from first-generation TNF inhibitors to newer IL-17 and IL-23 inhibitors such as bimekizumab and risankizumab, respectively. Recent research has added more data to the literature on long-term efficacy, sequencing of therapies, and comparison studies of biologics.1,2,3
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center, has served as an investigator for pivotal trials evaluating a number of biologics including guselkumab and secukinumab.
HCPLive® spoke with Mease to learn more about the trajectory that biologics have followed in the PsA field and how the field has continued to integrate more biologics into the treatment landscape. He also discussed different targets and recent research on new and upcoming biologics.
“We are now getting more and more choices, so as we strive to get patients into minimal disease activity state and maintain them there, even when we lose effect with one drug or one mechanism, we've now got others to be able to cycle to, and that's very helpful for us,” Mease told HCPLive.
Relevant disclosures include AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Genentech, Janssen, Novartis, Pfizer Inc, Sun and UCB.
REFERENCES
Walsh J, Merola J, Tillett W, et al. Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies. Presented at the 2024 ACR Convergence. Washington, DC. 14-19 November.
Gordon, K.B., Blauvelt, A., Bachelez, H. et al. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials. Dermatol Ther (Heidelb). Published online August 17, 2024. doi: 10.1007/s13555-024-01238-5
McInnes IB, Sewerin P, Sharaf M, Efficace M, Lavie F, Zimmermann M, Coates LC. Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial. RMD Open. 2024 Dec 12;10(4):e004494. doi: 10.1136/rmdopen-2024-004494. PMID: 39672591.
